Parexel, AMC partner to advance drug development programs in Korea
Parexel has signed an agreement with ASAN Medical Center (AMC) to accelerate Korea based drug development and commercialization programs.
As per the agreement, clinical trial sponsors based regionally and internationally will have access to clinical trial services throughout Asia, with a focus on early phase development.
Parexel International COO Mark Goldberg said through the collaboration with ASAN they look forward to help clients take advantage of opportunities to support their Korea-based development and commercialization programs
"Parexel provides clients with patient access in key therapeutic areas for early phase development through our early phase units and global alliance network," Goldberg added.
ASAN president and CEO Seong-Wook Park said they are collaborating with Parexel through their Department of Clinical Pharmacology and Therapeutics to facilitate, and enhance the development and use of pharmacotherapeutics.
Related Insight
Suppliers Directory
Vetter Pharma International - High-Quality Aseptically Pre-Filled Injection Systems
From preclinical development through commercial supply.
Contract Research & Services > Contract Services > Suppliers
Pharma IQ - Workshops, Conferences and Training Courses for Pharmaceutical Professionals
Pharma IQ, a division of IQPC, provides a forum to address the critical issues facing the Pharmaceutical Industry today. Pharma IQ utilises workshop, conference and training course formats to facilitate a learning environment for pharmaceutical professionals working in all areas of drug development: from Discovery to Post-Marketing.
Contract Research & Services > Contract Services > Suppliers
Penn Pharma - Drug Development, Clinical Supplies & Contract Manufacturing Solutions
Penn Pharma is a leading provider of fully integrated and cost effective pharmaceutical development, clinical supply and manufacturing and packing services to the international healthcare industry, whose services support a fast and effective route from clinic to market. Penn provides unparalleled service offerings developed over its 30 year trading history.
Contract Research & Services > Contract Services > Suppliers
eResearch Technology - Provider of Technology and Services
Based in Philadelphia, PA, ERT is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis.
Contract Research & Services > Contract Services > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Services Intelligence
ILS Client List
Published by Investigator Location Services
Contract Research & Services > Contract Services > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.